PDX1 and neoplasm: As before, Pdx1-Cre; KrasG12D; p53R172H; E-cadherin-GFP mice were allowed to form tumors for ∼150 days and, upon signs of tumor burden, were placed on daily dasatinib treatment (10 mg/kg) for 3 consecutive days (Figure 6A), followed by FRAP analysis (Figure 6B; Movie S7).